Mark Oldendorf, MD
Internal Medicine · Loudonville, NYNPI 1427147800
Payments from drug & device makers
Across 219 payments — averaging $18.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$544
- Novo Nordisk$517
- Lilly USA, LLC$355
- Otsuka America Pharmaceutical, Inc.$345
- Sumitomo Pharma America, Inc.$181
- Merck$178
- plus $2K from 32 others
What the payments were for
- Food & beverage$4,01299%
- Education$321%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 32 | $544 |
| Novo Nordisk | 21 | $517 |
| Lilly USA, LLC | 21 | $355 |
| Otsuka America Pharmaceutical, Inc. | 13 | $345 |
| Sumitomo Pharma America, Inc. | 11 | $181 |
| Merck | 11 | $178 |
| Exact Sciences | 8 | $156 |
| Lundbeck LLC | 8 | $154 |
| Teva Pharmaceuticals USA, Inc. | 8 | $149 |
| Astellas Pharma US Inc | 7 | $122 |
| AstraZeneca | 9 | $120 |
| Abbott | 5 | $98 |
| Pfizer | 5 | $87 |
| Hologic Sales And Service, LLC | 3 | $86 |
| Johnson & Johnson | 5 | $82 |
| GSK | 5 | $78 |
| Indivior Inc. | 4 | $77 |
| Axsome Therapeutics, Inc. | 5 | $74 |
| Boehringer Ingelheim | 5 | $73 |
| Idorsia Pharmaceuticals US Inc | 4 | $57 |
| Sunovion Pharmaceuticals Inc. | 2 | $43 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $40 |
| Braeburn Inc. | 2 | $40 |
| Amgen | 2 | $38 |
| Dexcom, Inc. | 2 | $38 |
| Collegium Pharmaceutical, Inc. | 2 | $35 |
| Orexo US, Inc. | 2 | $29 |
| Seqirus USA Inc | 2 | $29 |
| Currax Pharmaceuticals LLC | 2 | $28 |
| Sanofi Pasteur Inc. | 1 | $28 |
| Amarin Pharma, Inc. | 2 | $28 |
| IBSA Pharma Inc. | 2 | $25 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $25 |
| Corium, LLC | 1 | $22 |
| Regeneron Healthcare Solutions, Inc. | 1 | $18 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| Bayer | 1 | $14 |
| Biohaven Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Wegovy$119
How this compares
$4,045 in reported general payments places this provider in the 85th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 83 | $89,478 |
| OzempicSemaglutide | 53 | $54,250 |
| JanuviaSitagliptin Phosphate | 21 | $26,087 |
| XareltoRivaroxaban | 30 | $24,795 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 20 | $12,654 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 16 | $11,995 |
| LunestaEszopiclone | 13 | $10,823 |
| Aimovig AutoinjectorErenumab-Aooe | 12 | $8,878 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 13 | $8,125 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 262 | $7,736 |
| Morphine Sulfate ErMorphine Sulfate | 36 | $7,227 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 49 | $6,968 |
| NexiumEsomeprazole Magnesium | 12 | $5,400 |
| Levothyroxine Sodium | 186 | $5,260 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 24 | $4,371 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $73 | $89,47883 claims |
| Novo NordiskOzempic | $517 | $54,25053 claims |
| MerckJanuvia | $178 | $26,08721 claims |
| Johnson & JohnsonXarelto | $82 | $24,79530 claims |
| AstraZenecaBreztri Aerosphere, Nexium | $120 | $13,52525 claims |
| GSKTrelegy Ellipta | $78 | $12,65420 claims |
| Indivior Inc.Suboxone | $77 | $11,99516 claims |
| AbbVieSynthroid | $544 | $3,65748 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in Loudonville
- Helena YuNew York$50.9M
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- David DoveEast Hampton$12.3M
- Robert CupeloEast Syracuse$10.6M
- Patrick ReaganRochester$9.4M
- Sally LauNew York$8.4M
- Angela BrancheRochester$7.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.